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Introduction 44
Diarrheal disease is the second leading cause of death in children under 5 years of age, 45 with nearly 1.7 billion cases and 525,000 deaths each year (1). Since their discovery in 1975, 46 human astroviruses have consistently ranked among the leading causes of diarrhea worldwide 47
(2). However, human astrovirus infections can range anywhere from asymptomatic to mild 48 diarrhea and even fatal systemic disease (3, 4) . Infections in immunocompetent individuals 49 typically present as watery diarrhea that resolves within 1 to 3 days post-infection without the 50 need for hospitalization (2). Astrovirus outbreaks of frequently occur in assisted living facilities, 51 hospitals and child care centers, where the young, elderly, and immunocompromised populations are at risk of persistent diarrhea leading to wasting (5), and extra-gastrointestinal 53 disease that requires medial intervention, including respiratory disease (6-10), and fatal 54 encephalitis, and meningitis (11) . 55
Despite its high prevalence and the risk of severe disease, no vaccines or drug 56 treatments exist for astrovirus. Only oral or parenteral fluids and electrolytes available to prevent 57 and treat dehydration caused by astrovirus-induced diarrhea. In these studies, we provide the 58 first evidence that nitazoxanide (NTZ), an FDA-approved broad-spectrum anti-parasitic and anti-59 viral drug, inhibits the replication of multiple strains of human astrovirus in vitro even when 60 administered up to 8 hours post-infection, and reduces viral shed and diarrhea in vivo. This work 61 highlights the potential use of NTZ as an effective therapeutic strategy against astrovirus 62 infection. 63
64
Results 65
Nitazoxanide blocks astrovirus replication in vitro by inhibiting dsRNA production. To 66 identify an effective antiviral drug against astrovirus, human colon carcinoma (Caco-2) cells 67 were infected with a laboratory strain of human astrovirus strain-1(HAstV-1) at a multiplicity of 68 infection (MOI) of 1 before increasing concentrations of foscarnet, ribavirin, acyclovir, 69 nitazoxanide or DMSO (vehicle control) were added 1 hour post-infection (hpi). Viral capsid 70 protein levels were quantitiated at 24 hpi by immunofluorescent microscopy as described (12). 71
Foscarnet, ribavirin, and acyclovir failed to inhibit HAstV-1 replication even at concentrations of 72 250 μM ( Figure 1a ). In contrast, NTZ inhibited HAstV-1 replication in a dose-dependent manner 73 with the 5 M treatment completely blocking virus replication (Figure1a-b). The 50% effective 74 concentration was calculated as approximately 1.47 μM ( Figure 1c ). Concentrations of NTZ 75 above 5 μM were associated with decreased cell viability as compared to vehicle alone (DMSO) 76 ( Figure 1d ). Thus, subsequent studies were performed with NTZ at a concentration of 2.5 μM. 77
To determine the stage of the viral replication cycle blocked by NTZ, drug was added at 78 2, 4, 6, 8, and 12 hours after HAstV-1 infection and viral capsid expression quantitated ( Figure  79 2a). Addition of NTZ up to 8hpi completely inhibited HAstV-1 replication ( Figure 2b) suggesting 80 it blocks an early stage of the viral life cycle. Indeed, NTZ reduced the formation of double-81 strand RNA that occurs when the astrovirus genome is generated via its RNA-dependent RNA 82 polymerase ( Figure 2c ). This method serves as a proxy for early replication given our lack of 83 antibodies to the HAstV-1 non-structural proteins. Since NTZ appeared to exert antiviral activity 84 early in the astrovirus replication cycle, we asked if NTZ activated any innate antiviral pathways. 85
Previous research has shown thiazolides, the active form of NTZ, up-regulate type I and II IFN 86 (13), HAstV has already been shown to be sensitive to IFN treatment, where exogenous 87 addition of IFNβ limited astrovirus replication in a dose-dependent manner (14). We treated 88
Caco-2 cells with NTZ and looked for up-regulation of type I and III interferons (IFN). At 4 hours 89 post NTZ treatment, the shortest amount of time in which NTZ still inhibits HAstV replication, 90 IFNα, IFNβ, or IFNλ were not significantly up-regulated compared to non-treated cells ( Figure  91 2f). This suggests that the induction of IFN is not the mechanism by which NTZ blocks HAstV 92
replication. 93
Finally, we asked if NTZ was effective against multiple HAstV serotypes and clinical 94 isolates. Briefly, Caco-2 cells were infected with four different lab-adapted HAstV serotypes 95 
NTZ reduces viral replication and clinical disease in vivo.
To determine if NTZ reduced 106 disease, we used the only small animal model exhibiting astrovirus-induced diarrheal disease, 107 turkey poults (15). Briefly, 5 day old turkey poults were orally gavaged with 100 mg/kg NTZ once 108 daily for 4 days prior to oral infection with intestinal filtrate containing between 10 12 -10 13 109 genome copy units turkey astrovirus (TAstV-2) in 500 μl PBS and 3 days post-infection (Fig 4a) . Our study provides the first evidence of an effective antiviral for astrovirus infection. We 120 showed NTZ is broadly protective against multiple HAstV serotypes and reduces the production 121 of dsRNA during infection in vitro with an EC 50 of approximately 1.47 μM. Additionally, we 122 showed the potential NTZ has as a clinical therapeutic by its ability to reduce viral shed and 123 clinical disease in our symptomatic turkey poult model. C virus (24, 30). Its mechanism of action against protozoa is due to its interference with 133 pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reactions (31). 134
While its antiviral action is currently unknown, research suggests it may be through the induction 135 of the interferon response via activation of protein kinase R, or disruption of the unfolded protein 136 response (17). We show that NTZ disrupts astrovirus infection early in the replications cycle 137 causing a significant decrease in the production of dsRNA. The inhibition by NTZ at an early 138 stage of infection was also seen with JEV (21). Recent research has shown thiazolides up-139 regulate type I and II IFN (13) , which modulate the immune system and could be how NTZ 140 creates a broadly antiviral state. However, the rapid kinetics with which NTZ inhibits HAstV 141 replication ( Figure 2 ) suggests that the induction of IFN is not responsible. 142
Astroviruses are classified into genotypes, but within the classical human genotype, 143
Mamastrovirus 1 (MAstV1), strains are further divided into serotypes (HAstV-1-8) based on their 144 antigenicity and genetic differences in the complete capsid sequence (2). These genetic 145 differences between astrovirus serotypes can confer differences in replication kinetics and 146 symptom severity (32). Thus, finding a compound that broadly inhibits astroviruses across 147 genotypes and serotypes is crucial. We found that NTZ is broadly protective across multiple 148
HAstV serotypes, including the dominant strain worldwide, HAstV-1 (33), and patient isolates. have been associated with eight cases of encephalitis or meningitis (11), with VA1 being 153 identified in five of those cases. Since the 1980's, the incidence of classic HAstV has been 154 declining (5), studies have shown seroprevalence of VA1 and MLB1 is 65% (34) and 86% (35), respectively, and could account for the displacement of circulating classic HAstV. Testing the 156 susceptibility of primary astrovirus isolates as well as non-classical HAstV to NTZ increases our 157 confidence that this drug would be effective in a clinical setting against circulating strains of 158
HAstV. 159
Turkey poults exhibit age-dependent diarrhea similar to humans when infected with 160
TAstV making them the only clinically relevant small animal model for astrovirus identified to 161 date (15, 36). We found that NTZ reduced virus levels shed in stool. We found a significant 162 decrease in stool viral titers with NTZ-treated poults having nearly 2 logs less virus at 5 days 163 post-infection. We also showed that viral titers began to plateau in the NTZ-treated poults at 5 164 days post-infection while untreated poults still showed increasing titers. This suggests NTZ 165 treatment may lead to faster clearance of the virus, however additional studies taken out further 166 are needed to definitively prove this. 167
These studies were repeated, however, due to the seasonality of turkey breeding and 168 limited availability of poults, a different breed of turkey, royal palm, was used. With the royal 169 palm poults, we again saw a reduction of viral titer in the stool. Additionally, we tested the small 170 intestinal tissue to quantitate viral RNA. The reduction in stool titers was recapitulated in the 171 tissue, where NTZ-treated poults had 2 logs lower virus in the duodenum, and about 1 log lower 172 virus in both the jejunum and the ileum (data not shown). However, NTZ-treatment had no effect 173 on the reduction of clinical symptoms in the royal palm poults. The mechanism by which TAstV-174 2 induces diarrhea could be why this reduction was not statistically significant throughout 175 infection. We know that administration of capsid alone is sufficient to induce diarrhea in turkey 176 poults (16). From our in vitro work we believe NTZ blocks replication around the point where the 177
AstV genome is copied. Therefore, NTZ treatment may not be able to fully inhibit AstV-induced 178 diarrhea. In addition to this point, we administered between 10 12 -10 13 genome copy units to TAstV-2 stocks were prepared from intestines collected from infected turkey poults. Briefly, 203 pieces of intestine were suspended in 0.5 ml PBS in multiple tubes, homogenized using 2-mm 204 zirconium oxide beads (Next Advance) beads for 4 minutes on speed setting 4 (Next Advance 205 air cooling bullet blender), and pelleted by centrifugation at 12,000 rpm for 5 minutes. The TAstV-2 genome copies were determined as previously described (16). Briefly, viral RNA was 251 Turkey poults (n=6/group) were infected with turkey astrovirus (TAstV-2) from intestinal filtrate. 400
Four days prior to infection and three days post-infection poults were treated with NTZ. Poults 401 were monitored for clinical score daily and stool was collected to measure viral RNA titer every 402 other day. (B) Percentage of poults with clinical scores of 3 or higher in the groups: NTZ 403 treatment alone (green circle), no antiviral treatment (gray square), TAstV-2 infected without 404 antiviral treatment (black triangle), and TAstV-2 infected with NTZ treatment (green triangle). (C) 405 Viral RNA titer of stool collected from infected poults with NTZ treatment (green triangles) or no 406 antiviral treatment (black triangles). All error bars indicate standard error of the means, and 407 dashed line represents the limit of detection. 408
